Form 8-K - Current report:
SEC Accession No. 0001193125-25-043544
Filing Date
2025-03-03
Accepted
2025-03-03 09:10:13
Documents
17
Period of Report
2025-03-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d803084d8k.htm   iXBRL 8-K 34722
2 EX-4.1 d803084dex41.htm EX-4.1 88691
3 EX-4.2 d803084dex42.htm EX-4.2 84039
4 EX-4.3 d803084dex43.htm EX-4.3 87136
5 EX-10.1 d803084dex101.htm EX-10.1 176341
  Complete submission text file 0001193125-25-043544.txt   715486

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA aktx-20250302.xsd EX-101.SCH 2507
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE aktx-20250302_lab.xml EX-101.LAB 17202
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aktx-20250302_pre.xml EX-101.PRE 10786
20 EXTRACTED XBRL INSTANCE DOCUMENT d803084d8k_htm.xml XML 3653
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 25694338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)